Sort
15,273 grants matching “antimicrobial resistance”
Staphylococcus aureus SPREAD (S. aureus Study of Prevalence Resistance and Environmental Dissemination)
$762,141Michael Zdenek David · University Of Pennsylvania · R01 · FY2025 · AI
Optimizing phagocyte activity against antibiotic resistant pathogens
$761,943Victor Nizet · University Of Chicago · U54 · FY2013 · AI
Antimicrobial, Angiogenic Skin Substitutes for Diabetic*
$761,545John M Centanni · Stratatech Corporation · R44 · FY2006 · DK
Optimization and Lead Selection of Novel Antimycobacterial Agents
$761,426Thale Cross Jarvis · Crestone, Inc. · R44 · FY2015 · GM
Transcriptional Profiling to Discriminate Bacterial and Non-bacterial Respiratory Illnesses
$761,271Ann R Falsey · University Of Rochester · R01 · FY2020 · AI
Use of De Novo Synthesis Approaches and Structure-guided Design to Optimize Therapeutic Properties of Streptothricin Class Antimicrobials
$761,258James E Kirby · Beth Israel Deaconess Medical Center · R01 · FY2024 · AI
Antibiotics : Studies on the Biological Mechanisms of Antibiotics
$761,164Daniel E Kahne · Harvard University · R01 · FY2025 · AI
Combination host-directed and antibacterial therapy for pulmonary intracellular infections
$760,910Patrick S. Stayton · University Of Washington · R01 · FY2025 · AI
Genomics of S. Aureus Colonization after Initial and Recurrent Skin Infections and the Impact of Antibiotics
$760,621Michael Zdenek David · University Of Pennsylvania · R01 · FY2021 · AI
Next-generation phenotypic antimicrobial susceptibility test platform: rapid results and comprehensive menus
$760,449Eric Stern · Selux Diagnostics, Inc. · R44 · FY2019 · AI
Task A42: Therapeutic Testing in Murine Models of Bacterial Thigh, Lung and Peritonitis Infections
$760,250Lyne Miesel · Pharmacology Discovery Services Taiwan, Ltd. · N01 · FY2020 · AI
RISK FACTORS FOR DRUG RESISTANT PNEUMOCOCCAL PNEUMONIA
$760,103University Of Pennsylvania · R01 · FY2002 · AI
Optimization of Atypical Antimycobacterial Carbapenem Antibiotics
$759,402John D Buynak · Southern Methodist University · R01 · FY2023 · AI
Neuronal Latency and Toxoplasma
$759,375Christopher A Hunter · University Of Pennsylvania · R01 · FY2023 · AI
A cross protective multivalent vaccine for Shigella and ETEC
$759,261David A Sack · Johns Hopkins University · R01 · FY2024 · AI
Noninvasive Treatment of Biofilm on Metallic Implants
$759,212John Charles Tepper · Solenic Medical Inc · R44 · FY2021 · AI
Developing therapeutics to treat chronic infections
$758,554Richard Edward Lee · St. Jude Children'S Research Hospital · R01 · FY2016 · AI
Developing therapeutics to treat chronic infections
$758,554Richard Edward Lee · St. Jude Children'S Research Hospital · R01 · FY2015 · AI
Novel Drug Discovery against P. falciparum ENR
$758,543James C Sacchettini · Texas A&M Agrilife Research · P01 · FY2007 · AI
Evolution, transmission, and control of drug-resistant tuberculosis
$758,488Theodore H Cohen · Yale University · R01 · FY2024 · AI
Integrated Multi-omics of Melioidosis
$758,287Timothy Eoin West · University Of Washington · R01 · FY2021 · AI
Trial to Reduce Antimicrobial Use in Nursing home residents with Alzheimer's disease and other Dementias (TRAIN-AD)
$758,262Susan L Mitchell · Hebrew Rehabilitation Center For Aged · R37 · FY2023 · AG
Neuronal Latency and Toxoplasma
$758,145Christopher A Hunter · University Of Pennsylvania · R01 · FY2020 · AI
Exploiting antibody catalysis for treating Cryptococcosis
$757,763Arturo Casadevall · Johns Hopkins University · R01 · FY2022 · AI
Establishing the Genetic Basis of Altered Drug Responses in Mycobacterium tuberculosis
$757,722Sarah M Fortune · Harvard Medical School · U19 · FY2020 · AI